(Q39358634)

11 September 2017

0 references

The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection (English)

1 reference

11 September 2017

0 references

Punnee Pitisuttithum

1

1 reference

11 September 2017

Alain Bouckenooghe

series ordinal

2

1 reference

11 September 2017

publication date

12 May 2016

1 reference

Expert Review of Vaccines

11 September 2017

published in

1 reference

11 September 2017

volume

15

1 reference

11 September 2017

issue

7

1 reference

11 September 2017

page(s)

795-798

1 reference

The global distribution and burden of dengue

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1189331

Dengue virus pathogenesis: an integrated view

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1189331

The changing incidence of dengue haemorrhagic fever in Indonesia: a 45-year registry-based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1189331

Economic impact of dengue illness in the Americas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1189331

Economic and disease burden of dengue in Southeast Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1189331

Global spread of dengue virus types: mapping the 70 year history

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1189331

Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1189331

Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1189331

Efficacy of a tetravalent dengue vaccine in children in Latin America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1189331

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1189331

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1189331

Dengue vaccine: hypotheses to understand CYD-TDV-induced protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1189331

Points for Consideration for dengue vaccine introduction - recommendations by the Dengue Vaccine Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1189331

The privilege and responsibility of having choices: decision-making for new vaccines in developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1189331

Preparing for dengue vaccine introduction in ASEAN countries: recommendations from the first ADVA regional workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1189331

Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: Utility for efficacy evaluation and impact of future vaccine introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1189331

Preparing for dengue vaccine introduction: recommendations from the 1st dengue v2V International Meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1189331

10.1080/14760584.2016.1189331

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference